Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...
Bayer's position has been that Kerendia is not so much in direct competition with the SGLT2s, but rather is a complementary therapy that can be used alongside them to improve the treatment options ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Finerenone (Kerendia) yielded minimal renal benefit in patients with heart failure with mildly reduced or ...
The thinking was that the drug could be a possible rival to Bayer’s approved chronic kidney disease (CKD) drug Kerendia. But those ambitions went up in flames in July when a prespecified interim ...
Cyclobenzaprine HCl 5mg, 7.5mg, 10mg; tabs. Cyclobenzaprine HCl relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to ...
After inj therapy: 17–64yrs (normal renal function): 20mg once then 10mg every 4–6 hours; max 40mg/day. ≥65yrs, or <110lbs, or renal impairment: 10mg once then 10mg every 4–6 hours ...